Elaine M. Hylek
YOU?
Author Swipe
View article: Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trial Open
Background and Aims Oral anticoagulation reduces stroke risk in patients with atrial fibrillation (AF) but increases bleeding. Longer fibrin clot lysis time has been shown to predict adverse cardiovascular outcomes in acute coronary syndro…
View article: Performance of Atrial Fibrillation Burden Trends for Stroke Risk Stratification
Performance of Atrial Fibrillation Burden Trends for Stroke Risk Stratification Open
BACKGROUND: Atrial fibrillation (AF) is associated with an increased risk of stroke, yet the limitations of conventional monitoring have restricted our understanding of AF burden risk thresholds. Predictive algorithms incorporating continu…
View article: Using Atrial Fibrillation Burden Trends and Machine Learning to Predict Near-Term Risk of Cardiovascular Hospitalization
Using Atrial Fibrillation Burden Trends and Machine Learning to Predict Near-Term Risk of Cardiovascular Hospitalization Open
BACKGROUND: Atrial fibrillation is associated with an increased risk of cardiovascular hospitalization (CVH), which may be triggered by changes in daily burden. Machine learning of dynamic trends in atrial fibrillation burden, as measured …
View article: Use of continuous cardiac monitoring to assess the influence of atrial fibrillation burden and patterns on patient symptoms and healthcare utilization: The DEFINE AFib study
Use of continuous cardiac monitoring to assess the influence of atrial fibrillation burden and patterns on patient symptoms and healthcare utilization: The DEFINE AFib study Open
The DEFINE AFib study will provide valuable insights into the association between dynamic measures of AF and AFHCU in a patient population with known AF. The results may demonstrate the impact of ICM-detected AF on patient outcomes and hel…
View article: Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries
Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD‐AF and ORBIT‐AF registries Open
Background An unmet need exists to reliably predict the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs). Hypothesis An externally validated model improves ICH risk str…
View article: PO-03-053 IMPACT OF PATIENT ACCESS TO ATRIAL FIBRILLATION BURDEN DATA DETECTED VIA INSERTABLE CARDIAC MONITOR
PO-03-053 IMPACT OF PATIENT ACCESS TO ATRIAL FIBRILLATION BURDEN DATA DETECTED VIA INSERTABLE CARDIAC MONITOR Open
View article: Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop
Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop Open
Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with …
View article: Milvexian for the Prevention of Venous Thromboembolism
Milvexian for the Prevention of Venous Thromboembolism Open
Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Bristol Myers Squibb and…
View article: Reexamination of the Embolic Stroke of Undetermined Source Concept
Reexamination of the Embolic Stroke of Undetermined Source Concept Open
Occult atrial fibrillation (AF) is a leading cause of stroke of unclear cause. The optimal approach to secondary stroke prevention for these patients remains elusive. The term embolic stroke of undetermined source (ESUS) was coined to desc…
View article: Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas Open
Objectives Growth differentiation factor 15 (GDF-15) is a biomarker independently associated with bleeding and death in anticoagulated patients with atrial fibrillation (AF). GDF-15 is also used as one component in the more precise biomark…
View article: Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials
Evaluation of the Age, Biomarkers, and Clinical History–Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials Open
These findings suggest that the ABC-bleeding risk score identifies patients with different risks of bleeding when combining aspirin and oral anticoagulation. The ABC-bleeding risk score may, therefore, be a useful tool for decision support…
View article: The importance of adherence and persistence in the elderly atrial fibrillation patient
The importance of adherence and persistence in the elderly atrial fibrillation patient Open
Older adults with atrial fibrillation are at the highest risk of ischaemic stroke yet are the least likely to be prescribed anticoagulant therapy, adhere to this therapy, and maintain long-term persistence with this therapy. The reasons fo…
View article: Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018
Trends in Atrial Fibrillation Incidence Rates Within an Integrated Health Care Delivery System, 2006 to 2018 Open
In this community-based study, AF incidence rates increased significantly during the study period. Concurrent increases were observed in AF risk factors in the at-risk population and short-term ECG use.
View article: Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials
Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials Open
View article: Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial
Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial Open
Background Cardiac troponin T (cTnT) and I (cTnI) concentrations provide strong prognostic information in anticoagulated patients with atrial fibrillation (AF). Whether the associations between cardiac troponin concentrations and mortality…
View article: Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation Open
Background: Atrial fibrillation (AF) adversely impacts health-related quality of life (hrQoL). While some patients demonstrate improvements in hrQoL, the factors associated with large improvements in hrQoL are not well described. Methods: …
View article: Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation Open
Background: Studies evaluating the effects of atrial fibrillation (AF) catheter ablation versus antiarrhythmic therapy on outcomes have shown mixed results. In addition, guidelines recommend continuing oral anticoagulation (OAC) after abla…
View article: Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial
Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial Open
Background: The use of nonsteroidal anti-inflammatory drugs (NSAIDs) with oral anticoagulants has been associated with an increased risk of bleeding. We investigated the risk of bleeding and major cardiovascular outcomes in patients with a…
View article: Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial
Effects of apixaban compared with warfarin as gain in event-free time – a novel assessment of the results of the ARISTOTLE trial Open
Background A novel approach to determine the effect of a treatment is to calculate the delay of event, which estimates the gain of event-free time. The aim of this study was to estimate gains in event-free time for stroke or systemic embol…
View article: Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment
Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment Open
Idarucizumab completely reverses dabigatran in >98% of patients regardless of renal function. Although re-elevation of dabigatran levels within 12 to 24 h is more common with renal impairment, the time to bleeding cessation and the extent …
View article: Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Open
Three metrics of prior warfarin control were associated with bleeding risk but only marginally more so than traditional clinical factors. This study did not identify any measures of INR control that were significantly associated with strok…
View article: Biomarkers for Prediction of Stroke and Bleeds in Atrial Fibrillation
Biomarkers for Prediction of Stroke and Bleeds in Atrial Fibrillation Open
View article: The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations Open
Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban and rivaroxaban, which inhibit factor Xa. In large clinical trials comparing the NOACs with the vitamin K …
View article: Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle
Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle Open
In the October issue of Thrombosis and Haemostasis, Geng et al reported treatment satisfaction with dabigatran versus warfarin among patients with atrial fibrillation (AF) in China.[1] This time-intensive, patient-centred study with high c…
View article: Apixaban for End-Stage Kidney Disease
Apixaban for End-Stage Kidney Disease Open
Article, see p 1519 T he use of vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) among patients dependent on dialysis remains controversial.In this population, VKAs are associated with higher rates of major bl…
View article: Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF Open
Background Chronic kidney disease ( CKD ) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control. Methods and Results Patients enrolled in ORBIT…
View article: Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation Open
Objectives Compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation (AF). Methods The biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events …
View article: Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA <sub>2</sub> DS <sub>2</sub> ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA <sub>2</sub> DS <sub>2</sub> ‐VASc Scores: Findings From the ORBIT‐AF I and II Registries Open
Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA 2 DS 2 VASc=1) (or women with CHA 2 DS 2 VASc=2) a variety of tr…
View article: P4453Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial
P4453Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial Open
View article: P976Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial
P976Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial Open